Work

Human papillomavirus (HPV) vaccination: clinical evidence and future vaccine directions

Year: 2026

Type: article

Abstract: Summary The introduction of prophylactic human papillomavirus (HPV) vaccines has been a major step forward in preventive oncology. Initial randomized trials demonstrated that vaccination effectively prevents persistent HPV infection and precancerous disease. More recently, population-based data have shown striking reductions in invasive cervical cancer. Long-term follow-up studies confirm sustained immunity without evidence of waning protection, indicating that booster doses are not required. Evidence is also accumulating that a single vaccine dose may provide protection comparable to two doses, a finding with major implications for affordability and global access. Reaching the World Health Organization 2030 elimination target will, however, require continued progress.

Source: memo - Magazine of European Medical Oncology

DOI: 10.1007/s12254-025-01090-z

Authors: Chiara Paternostro, Elmar A. Joura

Institutions: Comprehensive Cancer Center Vienna, Medical University of Vienna

Language: English

Topic: Cervical Cancer and HPV Research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,790